The correlation between single nucleotide polymorphism in XRCC1 and clinical response to platinum-based chemotherapy in ovarian cancer

CHENG Li; LI Lin; XING Hui

Abstract：Objective To investigate the relationship between XRCC1 Arg194Trp and Arg399Gln polymorphism genotype and chemosensitivity to platinum-based in ovarian cancer. Methods Polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) analysis was performed to detect 82 cases of XRCC1 Arg194Trp and Arg399Gln polymorphism genotype after platinum-based chemotherapy drugs up to six cycles of ovarian cancer. And the association between the two genes sites were analyzed. Results XRCC1 Arg194Trp had three genotypes, namely Arg/Arg, Arg/Trp, Trp/Trp, and frequency distribution was 47?6%, 43?9%, 8?5%, respectively. XRCC1 Arg399Gln had three genotypes, namely Arg/Arg, Arg/Gln, Gln/Gln, and frequency distribution was 25?6%, 40?2%, 34?1%, respectively. There were statistically significant difference of different genotypes in FIGO stage and age group ( P<0?05) . The genotypes existed difference between the group of sensitive to chemotherapy and non-sensitive to chemotherapy ( P<0?05) . XRCC1 Arg194Trp Trp/Trp genotype and Arg399Gln Gln/Gln genotype were easier to resistance to platinum drug compared with the Arg/Arg genotype, the odds ratio could be increased by 13?50 ( 95%CI:1?461-124?739) times and 7?65 ( 95%CI:2?012-29?088) times, respectively. While carrying 194Arg/Trp and 399Gln/Gln patients have 84?62% of non-sensitive to chemotherapy( OR=22?00,95%CI:2?534~190?998;P<0?05) . Conclusion Polymorphism in the XRCC1 Arg194Trp and Arg399Gln may have signifi-cant impact on the response of ovarian cancer to platinum-based chemotherapy;and the two gene sites have combined effect.